Learn the common signs of mental illness in adults and adolescents.
Learn more about common mental health conditions that affect millions.
Find Your Local NAMI
Call the NAMI Helpline at
Or in a crisis, text "NAMI" to 741741
Brand name: Zulresso®
Generic name: brexanolone (brex AN oh lone)
All FDA black box warnings are at the end of this fact sheet. Please review before taking this medication.
Brexanolone is an antidepressant medication that works in the brain. It is approved for the treatment of postpartum depression (PPD).
Symptoms of postpartum depression include:
Brexanolone may cause you to feel very sleepy (excessive sedation) or pass out (loss of consciousness). Your healthcare provider should check you for your symptoms of excessive sleepiness every 2 hours while you are awake.
During your brexanolone infusion, tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the infusion until your symptoms go away.
You must have a caregiver or family member with you to help care for your child(ren) during your brexanolone infusion.
Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness, brexanolone is only available through a restricted program called ZULRESSO REMS.
It is not known if brexanolone will harm your unborn baby. There is a pregnancy registry for females who are exposed to brexanolone during pregnancy. The purpose of the registry is to collect information about the health of females exposed to brexanolone and their baby. If you become pregnant during treatment with brexanolone, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/.
Let your healthcare provider know if you are breastfeeding or plan to breastfeed. Brexanolone passes into breast milk. Talk to your healthcare provider about the risks and benefits of breastfeeding and about the best way to feed your baby while receiving brexanolone.
Brexanolone is given to you by continuous intravenous (IV) infusion. Your brexanolone infusion will last for a total of 60 hours (2.5 days). A healthcare provider must be available on site to continuously monitor you for the duration of the infusion.
Brexanolone may make you feel dizzy and sleepy. Do not drive a car or do other activities that require mental alertness after your brexanolone infusion until your feeling of sleepiness has completely gone away.
Do not drink alcohol during your brexanolone infusion. Drinking alcohol while receiving brexanolone can increase the risk of excess sleepiness.
Common side effects
Sleepiness, dry mouth, diziness, passing out, or flushing of the skin or face.
Rare/serious side effects
Brexanolone can cause excessive sedation and loss of consciousness. Tell your health care provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out during your brexanolone infusion. Your health care provider may lower your dose or stop the infusion until your symptoms go away. Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness, brexanolone is only available through a restricted program called the ZULRESSO REMS.
There is a risk of physical and/or emotional dependence (addiction). Talk to your provider about the risk.
CNS depressants, such as benzodiazepines or opioids, may enhance the feeling of sedation when taken with brexanolone.
Suicidal Thoughts or Actions in Children and Adults
Postpartum depression and certain other psychiatric disorder are themselves associated with the risk of suicide. Women with postpartum depression, may experience worsening of their depression and/or emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications. This risk may persist until significant remission occurs. Brexanolone and other antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger. All patients being treated with antidepressants for any indication should watch for and notify their health care provider for worsening symptoms, suicidality and unusual changes in behavior, during treatment.
In clinical studies, brexanolone caused sedation and somnolence that required dose modification, or reduction in some patients during the infusion compared to the placebo treated patient. Some patients reported to have loss of consciousness or altered state of consciousness during the brexanolone infusion. Time to full recovery from loss of or altered state of consciousness, after dose interruption, ranged from 15 to 60 minutes. Patients, should be cautioned against engaging in potentially hazardous activities requiring mental alertness, such as driving, after infusion until any sedative effects of brexanolone have dissipated. Patients must be accompanied during interactions with their child(ren) while receiving the infusion because of the potential for excessive sedation and sudden loss of consciousness. Patients, their families, and caregivers should be alert to the emergency of excessive sedation and sudden loss of consciousness. If these symptoms emerge, they should be reported to the patient’s prescriber or health care professional.
©2020 The College of Psychiatric and Neurologic Pharmacists (CPNP) and the National Alliance on Mental Illness (NAMI). CPNP and NAMI make this document available under the Creative Commons Attribution-No Derivatives 4.0 International License. Last Updated: January 2016.
This information is being provided as a community outreach effort of the College of Psychiatric and Neurologic Pharmacists. This information is for educational and informational purposes only and is not medical advice. This information contains a summary of important points and is not an exhaustive review of information about the medication. Always seek the advice of a physician or other qualified medical professional with any questions you may have regarding medications or medical conditions. Never delay seeking professional medical advice or disregard medical professional advice as a result of any information provided herein. The College of Psychiatric and Neurologic Pharmacists disclaims any and all liability alleged as a result of the information provided herein.
Call the NAMI Helpline at
text "NAMI" to 741741